Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | RB1 | P06400 | 7/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25247033 | 1.00 | CYP2D6 (0.76) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL30455215 | 1.00 | CYP2D6 (0.76) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL25287616 | 1.00 | CYP2D6 (0.76) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| Hydrochloric Acid SCHEMBL4158280 | 0.99 | CYP2D6 (0.74) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL30455685 | 0.92 | CYP2D6 (0.69) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL25285965 | 0.91 | CYP2D6 (0.64) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL25249451 | 0.91 | CYP2D6 (0.64) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL25286477 | 0.91 | CYP2D6 (0.64) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL25286478 | 0.91 | CYP2D6 (0.64) | CYP2D6KCNH2RB1BRD3SIRT2 | |
| SCHEMBL20537338 | 0.87 | CYP2D6 (0.78) | CYP2D6KCNH2RB1BRD3SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | claimed |
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP2D6 994/4885KCNH2 4356/4885RB1 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.